“Ophthalmic Drugs Contract Manufacturing Market, 2020-2030” {Roots Analysis}
To order this 375+
page report, please visit this - https://www.rootsanalysis.com/reports/view_document/ophthalmic-drugs-cmo/294.html
Key Inclusions
§
A detailed review of
the ophthalmic drugs contract manufacturing market landscape, featuring a list
of over 240 CMOs and analysis based on a number of relevant parameters, such as
year of establishment, company size, geographical location, scale of operation
(preclinical, pilot, clinical, and commercial), type of product (APIs and
FDFs), type of FDF manufactured (solids, semi-solids, liquids, suspensions, and
injectables), type of primary packaging (ampoules / vials, glass / plastic
bottles, ointment tubes, sachets / pouches, blister packing, and other forms),
type of service(s) offered (pre-formulation, drug formulation, method
validation, process development, analytical testing, stability studies,
technology transfer, scale-up, fill / finish, and regulatory support), number
of manufacturing facilities, their specific locations (country-wise), as well
as their regulatory accreditations and certifications.
§
A company
competitiveness analysis, highlighting prominent ophthalmic drug contract
manufacturers based on supplier strength (which was calculated considering
the size of employee base of a company and its experience in this field)
and service strength (quantified based on type of FDF manufactured, type of
primary packaging, type of service(s) offered, scale of operation, number and
location of manufacturing facilities, and number of regulatory accreditations /
certifications)..
§
Elaborate profiles of
key players based in North America, Europe and Asia-Pacific that offer a
diverse range of capabilities for the development, manufacturing and packaging
of ophthalmic drug products. Each profile includes an overview of the company,
its financial performance (if available), information related to its
service portfolio, manufacturing facilities, and details on partnerships,
recent developments (expansions), and awards and accolades received, as well as
an informed future outlook.
§
A detailed clinical
trial analysis of completed, ongoing and planned studies of various ophthalmic
drug products, highlighting prevalent trends across parameters, such as current
trial status, trial registration year, enrolled patient population and trial
location, phase of development, study design, leading industry and non-industry
players (in terms of number of trials undertaken / conducted), study
focus, and key disease indications (in terms of number of trials undertaken
/ conducted).
§
An informed estimate
of the annual commercial demand for ophthalmic APIs and drug FDFs (in million
litres), taking into account the top 30 small molecule-based ophthalmic drugs;
the analysis takes into consideration the target patient population, dosing
frequency and dose strength of the aforementioned products. The annual clinical
demand for ophthalmic drug products was also estimated, taking into account
ongoing and planned clinical trials.
§
A detailed capacity
analysis, taking into consideration the manufacturing capacities of various
stakeholders (small-sized, mid-sized, and large-sized CMOs) in the market,
based on data gathered via secondary and primary research. It also provides the
likely distribution of the global ophthalmic product-related manufacturing
capacity available across different types of companies (small-sized, mid-sized,
and large-sized), scales of operation (preclinical, clinical and commercial),
types of FDFs manufactured (ampoules / vials, glass / plastic bottles, and
ointment tubes), and key geographical regions (North America, Europe, and
Asia-Pacific).
§
A discussion on
affiliated trends, key drivers and challenges, under a comprehensive SWOT
framework, which are likely to impact the industry’s evolution, including a
Harvey ball analysis, highlighting the relative effect of each SWOT parameter
on the overall industry.
§
A survey analysis
featuring inputs solicited from various experts who are directly / indirectly
involved in providing CMO services to ophthalmic drug developers.
§
A discussion on the
emerging trends and potential market drivers, such as the growing ophthalmic
drugs / therapies pipeline, rise in outsourcing activity for sterile
manufacturing operations, adoption of innovative technologies and increasing
opportunities in the Asia-Pacific region, which are likely to impact the
evolution of the market in the coming years.
§
A detailed list of
over 55 ophthalmic medical device contract manufacturers, along with
information on year of establishment, company size, geographical location, key
application area(s) (diagnostics, drug delivery, therapeutics, and others),
type of manufacturing service(s) offered (design, component manufacturing,
assembly, prototype development, sterilization, quality assurance, and
packaging), type of additional service(s) offered (consultancy, documentation,
inspection / testing, labelling, logistics, project management, regulatory support,
repair, warehouse / storage, and others), scale of operation (pilot and
commercial), device class-related expertise (class I, class II and class III),
number of manufacturing facilities, their specific locations (country-wise), as
well as their regulatory accreditations and certifications.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Type
of product
§
Ophthalmic API
§
Ophthalmic drug FDF
§
Type of FDF manufactured
§
Solid
§
Semi-solid
§
Liquid / suspension
§ Type
of primary packaging
§ Ampoule
/ vial
§ Glass
/ plastic bottle
§ Ointment
tube
§ Blister
packing
§ Other
forms
§ Scale
of manufacturing
§
Clinical
§
Commercial
§ Company
size
§
Small
§
Mid-sized
§
Large
§
Very large
§ Target
disease indication
§
Age-related macular degeneration
§
Dry eye
§
Glaucoma
§
Other disease segments
§ Key
geographical regions
§
North America (US, Canada and Mexico)
§
Europe (UK, Germany, France, Spain, Italy and rest of
Europe)
§
Asia-Pacific (India, China, Japan, Australia and rest of
Asia-Pacific)
§
Rest of the world
To request a sample
copy / brochure, please visit this - https://www.rootsanalysis.com/reports/294/request-sample.html
Key
Questions Answered
§
What is the clinical research landscape of investigational
ophthalmic drugs?
§
What percentage of ophthalmic drug manufacturing operations
are outsourced to service providers?
§
What are the preferred primary packaging formats / fill
finish containers of ophthalmic drugs?
§
Who are the leading contract manufacturers of ophthalmic
APIs and drug FDFs, across the globe?
§
What are the key challenges faced by ophthalmic drug
contract manufacturers?
§
What is the annual, clinical and commercial demand for ophthalmic
drugs?
§
What is the current, installed manufacturing capacity for
ophthalmic drugs?
§ What
are the anticipated future trends related to ophthalmic drug manufacturing?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
You may also be
interested in the following titles:
1. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
2. Pharmaceutical Continuous Manufacturing Market, 2020-2030
3.
Peptide Therapeutics:
Contract API Manufacturing Market, 2020-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Comments
Post a Comment